

Supplemental Table 1. AUC for insulin secretion rate and GLP1(7-36) per incretin effect group.


	High Incretin Effect (n=13)	Medium Incretin Effect (n=13)	Low Incretin Effect (n=13)	p
AUC _{SR-OGTT} (pmol*min/L)	46,958±5724	44,949±2625.1	50,544±5940	0.261
AUC _{SR-Iso-IVGTT} (pmol*min/L)	30,681±2414.2	37,413±2212.9	55,308±6429.6	<0.001
AUC _{ΔGLP-1(7-36)-OGTT} (%*min)	4,373±2982	1,902±1160	2,363±1,322	0.010
AUC _{ΔGLP-1(7-36)-Iso-IVGTT} (%*min)	899.4±1427	412.6±906.8	1,124±1,286	0.309

AUC_{SR-OGTT}, area under the curve for secretion rate during the oral glucose tolerance test (OGTT); AUC_{SR-Iso-IVGTT}, area under the curve for secretion rate during the isoglycemic intravenous glucose tolerance test (iso-IVGTT).

Supplemental Table 2. Multivariable logistic regression analysis for the binary outcome “low-incretin tertile”.

	β coefficient \pm SE	<i>p</i>
Sex (M)	-9.89 \pm 11.48	0.396
BMI (kg/m²)	0.03 \pm 0.91	0.974
Ethnicity*		
NHW	24.34 \pm 15.09	0.118
Hispanic	21.49 \pm 13.82	0.131
Glucose tolerance (IGT)	-15.14 \pm 10.19	0.148
Fasting glucose (mg/dL)	0.04 \pm 0.72	0.956
TCF7L2 genotype† (T risk allele)	-22.4 \pm 10.69	0.045

The reference groups is *NHW for ethnicity and †CC (wild type) genotype for *TCF7L2* rs7903146. *IGT*, impaired glucose tolerance; *BMI*, body mass index; NHW, non-Hispanic White; NHB, non-Hispanic Black.; SE, standard error. Data are expressed as mean \pm SE.
p<0.05 (bold)



Supplemental Figure 1. Hyperglycemic clamp with Arginine stimulation. Glucose (A), insulin (B), C-peptide derived indices (C) and C-peptide profile (D) in the Low-, Moderate- and High-incretin group. *ACPRg*, acute C-peptide response to glucose, *ACPRmax*, Arginine-C-peptide response after max glucose stimulation.